BioCryst to acquire Astria for $700M, adding a second HAE drug

BioCryst Pharmaceuticals plans to buy Astria Therapeutics for around $700 million in cash and stock. The deal, announced Tuesday, means BioCryst will get a drug intended to prevent hereditary angioedema ...